Cytek Biosciences (NASDAQ:CTKB) Shares Down 7.5%
Cytek Biosciences (NASDAQ:CTKB) Shares Down 7.5%
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) shares dropped 7.5% during mid-day trading on Thursday . The company traded as low as $10.91 and last traded at $10.92. Approximately 9,581 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 739,450 shares. The stock had previously closed at $11.81.
賽特克生物科技股份有限公司(納斯達克代碼：CTKB-GET Rating)股價週四午盤下跌7.5%。該公司股價低至10.91美元，最新報10.92美元。午盤成交量約為9,581股，較日均成交量739,450股減少99%。該股此前收盤價為11.81美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, Piper Sandler raised their price objective on Cytek Biosciences from $16.00 to $18.00 in a research report on Monday, November 14th.
另外，派珀·桑德勒在11月14日星期一的一份研究報告中將Cytek Biosciences的目標價從16.00美元上調至18.00美元。
Cytek Biosciences Price Performance
Cytek Bioscions性價比
The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -1,181.00 and a beta of 0.06. The stock has a 50-day moving average price of $11.91 and a 200-day moving average price of $12.97.
該公司市值14.7億美元，市盈率為-1181.00，貝塔係數為0.06。該股的50日移動均線價格為11.91美元，200日移動均線價格為12.97美元。
Insider Buying and Selling
內幕買賣
In related news, CEO Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $14.76, for a total transaction of $295,200.00. Following the completion of the sale, the chief executive officer now directly owns 7,785,820 shares of the company's stock, valued at approximately $114,918,703.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Cytek Biosciences news, CFO Patrik Jeanmonod sold 3,500 shares of the firm's stock in a transaction on Monday, October 24th. The stock was sold at an average price of $15.16, for a total transaction of $53,060.00. Following the transaction, the chief financial officer now owns 85,563 shares in the company, valued at approximately $1,297,135.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Wenbin Jiang sold 20,000 shares of the firm's stock in a transaction on Monday, November 7th. The stock was sold at an average price of $14.76, for a total value of $295,200.00. Following the transaction, the chief executive officer now owns 7,785,820 shares in the company, valued at approximately $114,918,703.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 126,500 shares of company stock valued at $1,618,745. Insiders own 15.90% of the company's stock.
在相關新聞中，首席執行官蔣文斌在11月7日星期一的一筆交易中出售了20,000股Cytek Biosciences股票。該股以14.76美元的平均價格出售，總成交金額為295,200.00美元。出售完成後，首席執行官現在直接擁有7,785,820股公司股票，價值約114,918,703.20美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過美國證券交易委員會網站。在Cytek Biosciences的其他新聞中，首席財務官Patrik Jeanmonod在10月24日星期一的一次交易中出售了3500股該公司的股票。股票以15.16美元的平均價格出售，總成交金額為53,060.00美元。交易完成後，這位首席財務官現在擁有該公司85,563股股票，價值約1,297,135.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。此外，首席執行官蔣文斌在11月7日星期一的一次交易中出售了2萬股該公司的股票。這隻股票的平均售價為14.76美元，總價值為295,200.00美元。交易完成後，這位首席執行官現在擁有該公司7,785,820股票，價值約114,918,703.20美元。關於這次銷售的披露可以找到這裏。在過去的90天裏，內部人士拋售了126,500股公司股票，價值1,618,745美元。內部人士持有該公司15.90%的股份。
Hedge Funds Weigh In On Cytek Biosciences
對衝基金參與Cytek Bioscions
A number of hedge funds have recently added to or reduced their stakes in CTKB. Royal Bank of Canada increased its stake in shares of Cytek Biosciences by 222.0% in the 3rd quarter. Royal Bank of Canada now owns 2,074 shares of the company's stock valued at $30,000 after purchasing an additional 1,430 shares during the last quarter. UBS Group AG increased its stake in shares of Cytek Biosciences by 6,269.8% in the 3rd quarter. UBS Group AG now owns 4,013 shares of the company's stock valued at $59,000 after purchasing an additional 3,950 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Cytek Biosciences by 54.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,077 shares of the company's stock valued at $74,000 after purchasing an additional 1,789 shares during the last quarter. Metropolitan Life Insurance Co NY increased its stake in shares of Cytek Biosciences by 31.5% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock valued at $69,000 after purchasing an additional 1,536 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Cytek Biosciences in the 2nd quarter valued at $70,000. Institutional investors own 49.48% of the company's stock.
一些對衝基金最近增持或減持了CTKB的股份。加拿大皇家銀行在第三季度增持賽特克生物科學股份222.0。加拿大皇家銀行在上個季度又購買了1,430股，現在持有該公司2,074股股票，價值3萬美元。瑞銀集團(UBS Group AG)第三季度增持Cytek Biosciences股份6,269.8%。瑞銀集團目前持有該公司4,013股股票，價值59,000美元，上一季度又購買了3,950股。AllSpring Global Investments Holdings LLC在第三季度增持了Cytek Biosciences的股份54.4%。AllSpring Global Investments Holdings LLC現在持有該公司5,077股股票，價值7.4萬美元，上個季度又購買了1,789股。紐約大都會人壽保險公司在第一季度增持了Cytek Biosciences的股份31.5%。紐約大都會人壽保險公司目前持有6,415股該公司股票，價值6.9萬美元，此前該公司在上個季度又購買了1,536股。最後，Lazard Asset Management LLC在第二季度購買了價值7萬美元的Cytek Biosciences股票的新頭寸。機構投資者持有該公司49.48%的股份。
Cytek Biosciences Company Profile
賽特克生物科學公司簡介
(Get Rating)
(獲取評級)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家細胞分析解決方案公司，提供細胞分析工具，促進生物醫學研究和臨牀應用的科學進步。它提供極光和北極光系統，這是一種光譜流動細胞儀，通過利用來自多個激光的熒光信號來區分單個細胞上的熒光標記來提供細胞分析；以及極光細胞分選系統，它利用全光譜圖譜技術進一步拓寬了細胞分析的潛在應用。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 3 Attractive Defensive Stocks With 3% Dividends
- 免費獲取StockNews.com關於Cytek生物科學的研究報告(CTKB)
- 愛彼迎的漲幅是否會像分析師預測的那樣達到38%？
- 特斯拉汽車降價是否意味着特斯拉股票也會降價？
- 微軟的裁員標誌着其他科技公司的裁員？
- 快速購買Fastenal的原因不止一個
- 3只有吸引力的防禦性股票，股息為3%
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cytek Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。